Darby Thomas, Ph.D., is Head of Patient Advocacy and Engagement at Stride Bio. She has been developing viral- and cell-based therapeutics for almost 20 years. Dr. Thomas came to StrideBio in June 2018 from Intrexon Corporation after serving in numerous roles, including Director of Rare Diseases. As Director of Rare Diseases, Dr. Thomas led multidisciplinary teams in the development of gene-modified cell-based therapeutics for recessive dystrophic epidermolysis bullosa and localized scleroderma, adeno-associated virus (AAV)-based gene therapy for Friedreich’s ataxia and numerous other preclinical programs. Prior to Intrexon, Dr. Thomas played an essential role in the development of AGTC’s AAV platform used for rare ophthalmic disease therapeutic development. A North Carolina native with a B.S. in Biology from University of North Carolina (UNC) at Chapel Hill, Dr. Thomas earned her doctorate in Molecular Virology from Baylor College of Medicine, followed by post-doctoral training at the University of Pennsylvania Perelman School of Medicine.
Darby Thomas, Ph.D.
HEAD, PATIENT ADVOCACY AND ENGAGEMENT